Major protease inhibitor
mutations developed in 6 of the 28 people (21%) taking Prezista versus 20 of 56 (36%) taking Kaletra.
The HIV protease inhibitor
project is valued atEUR 64m, of which EUR 2m is a license fee due on signing of the agreement.
Shortly after approval, the price was set at $25 a day (wholesale acquisition price)--at the low end of the last three protease inhibitors
approved (the ritonavir will cost extra).
Ritonavir has a potent effect on the cytochrome p450 3A4 enzymes in the liver such that when it is combined with another protease inhibitor
(or any drug that is metabolized or affected by this enzyme), drug levels of the other drug are dramatically increased and the resultant lowered metabolism causes the other drug to stay in the body for a longer period.
Fifty-three percent of the women had not received any anti-HIV drug before pregnancy, and 70% had not received a protease inhibitor
before pregnancy, said Dr.
Only patients' age and whether they were medically insured were associated with protease inhibitor
treatment among each sexual preference group, though not all were statistically significant.
Gives Impact analysis of approval of Victrelis (boceprevir) - First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
Approval in US
Delayed switching from a failing protease inhibitor
combination did not increase the risk of death or CD4-count failure during the study period.
ITMN-191 retains activity against variants that exhibit reduced sensitivity to other experimental HCV protease inhibitors
Growers now should try to breed soybeans with extra protein rich in the Bowman-Birk protease inhibitor
, Krishnan says.
Tipranavir is a non-peptidic protease inhibitor
(NPPI) for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients who are protease inhibitor
Vertex's investigational oral protease inhibitor
for the treatment of hepatitis C virus (HCV) infection, in Japan and certain Far East countries.
For example, Tibotec has 2 drugs in parallel development, a protease inhibitor
(PI) with good activity against PI-resistant virus and a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that overcomes viral resistance to other drugs of this type.
Four new medications debuted in 2003, but for 2004 only one--a protease inhibitor
called tipranavir--is expected to hit the market for so-called treatment-experienced patients like Getty.
Luber, executive director of research at Tower ID Medical Associates, Los Angeles, noted that amprenavir (Agenerase) is the only protease inhibitor
currently approved by the Food and Drug Administration for once-daily dosing.